Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Food is Medicine Clear all
Completed Not applicable Interventional

Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk

NCT05166525
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Interventions
Medically tailored meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • San Rafael, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313
View directory record Official record
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Fezolinetant, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

NCT05363631
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Interventions
Selenomethionine (SLM), Axitinib, Pembrolizumab
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Low Carbohydrate/High Protein Diet to Improve Metabolic Health

NCT03207841
View directory record Official record
Conditions
Spinal Cord, Metabolic Syndrome, Diabetes
Interventions
LC/HP
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients

NCT02389062
View directory record Official record
Conditions
Adult Form of Celiac Disease
Interventions
Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 29, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

NCT02057289
View directory record Official record
Conditions
Immunocompromised, Bone Marrow Transplant, Cancer
Interventions
Micafungin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transfemoral Socket Design and Muscle Function

NCT04212299
View directory record Official record
Conditions
Amputation
Interventions
Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder

NCT01615367
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Nutrition, Exercise, and Wellness (NEW) psychotherapy, Typically consists of at least one FDA-approved mood stabilizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

NCT01990079
View directory record Official record
Conditions
PTSD, Smoking
Interventions
Bupropion, nicotine replacement therapy, Smoking cessation counseling, mobile contingency management, Stay Quit Coach
Drug · Other · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Active, not recruiting Not applicable Interventional

Meals for Me: Drop Shipment Versus Personally-delivered Meals for Diabetes Management

NCT04277117
View directory record Official record
Conditions
Diabetes
Interventions
Waitlist, Medically tailored meals - Daily delivery with human interaction, Medically tailored meals - Weekly delivery with no human interaction, Medically tailored meals - Standard MOWCTX delivery with human interaction
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
55 Years to 90 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

NCT05925959
View directory record Official record
Conditions
Abdominal Wall Hernia
Interventions
Preoperative Weight Management Program
Other
Lead sponsor
Benjamin T. Miller
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

The Effectiveness of Kuvan in Amish PKU Patients

NCT02677870
View directory record Official record
Conditions
Phenylketonuria
Interventions
saproterin dihydrochloride, Diet treatment
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Phase 1 Interventional

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06549790
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
NMS-03597812
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
Duarte, California • Aurora, Colorado • Newark, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCT03230097
View directory record Official record
Conditions
Psychotic Disorders
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
16 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Culver City, California • San Diego, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT04740476
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen (STK-001)
Drug
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
30 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Withdrawn Not applicable Interventional

Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i

NCT06931197
View directory record Official record
Conditions
Contingency Management, Methamphetamine Use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Bioequivalence of a Combined Formulated Tablet

NCT01622790
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Cooking for Health Optimization and Disease Prevention (CHOP) Trial

NCT07011459
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Cooking class, Standard of care
Behavioral · Other
Lead sponsor
Tulane University
Other
Eligibility
55 Years to 120 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
View directory record Official record
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 29, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 29, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 29, 2026, 8:40 AM EDT
Recruiting Phase 3 Interventional

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478
View directory record Official record
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 29, 2026, 8:40 AM EDT